Rationale for and design of the idiopathic pulmonary fibrosis–PRospective outcomes (IPF-PRO) registry

BMJ Open Respiratory Research

Volumn 3, Issue 1, 2016, Pages

  O’Brien, Emily C ^a   Durheim, Michael T ^a   Gamerman, Victoria ^b   Garfinkel, Sandy ^b   Anstrom, Kevin J ^a   Palmer, Scott M ^a   Conoscenti, Craig S ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; TRANSCRIPTOME;

6 MINUTE WALK TEST; ARTICLE; CLINICAL PRACTICE; DISEASE REGISTRY; FIBROSING ALVEOLITIS; FUNCTIONAL STATUS ASSESSMENT; HOSPITALIZATION; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTICENTER STUDY; NUCLEIC ACID ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; SHORT FORM 12; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TERTIARY CARE CENTER; UNITED STATES;

EID: 84980315778     PISSN: None     EISSN: 20524439     Source Type: Journal    
DOI: 10.1136/bmjresp-2015-000108     Document Type: Article

References (34)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Mea 2011;183:788-824.
2. Nalysnyk L, Cid-Ruzafa J, Rotella P, etal. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012;21:355-61.
3. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014;2:566-72.
4. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82.
5. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92.
6. King TE Jr, Albera C, Bradford WZ, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med 2014;189:825-31.
7. Collard HR, Tino G, Noble PW, et al. Patient experiences with pulmonary fibrosis. Respir Med 2007;101:1350-4.
8. Schoenheit G, Becattelli I, Cohen AH. Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients. Chron Respir Dis 2011;8:225-31.
9. Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med 2011;184:842-7.
10. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:431-40.
11. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:963-7.
12. Mura M, Porretta MA, Bargagli E, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 2012;40:101-9.
13. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011;140:221-9.
14. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-43.
15. Collard HR, Yow E, Richeldi L, et al. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res 2013;14:73.
16. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. EurRespir J 2011;37:356-63.
17. Dimmock AEF, Chinchilli VM, Criner GJ, et al. The GAP Index predicts mortality in a statewide cohort of patients with idiopathic pulmonary fibrosis [abstract]. Am J Respir Crit Care Med 2013;187:A6086.
18. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:459-66.
19. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012;156:684-91.
20. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013;45:613-20.
21. Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013;1:309-17.
22. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011;364:1503-12.
23. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013;309:2232-9.
24. Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2014;307: L681-91.
25. Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res 2012;159:218-27.
26. Belkin A, Swigris JJ. Patient expectations and experiences in idiopathic pulmonary fibrosis: implications of patient surveys for improved care. Expert Rev Respir Med 2014;8:173-8.
27. Swigris JJ, Stewart AL, Gould MK, et al. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes 2005;3:61.
28. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010;104:296-304.
29. Swigris JJ, Fairclough D. Patient-reported outcomes in idiopathic pulmonary fibrosis research. Chest 2012;142:291-7.
30. Swigris JJ, Esser D, Conoscenti CS, et al. The psychometric properties of the St. George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes 2014;12:124.
31. Tomioka H, Imanaka K, Hashimoto K, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis—cross-sectional and longitudinal study. Intern Med 2007;46:1533-42.
32. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33.
33. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43.
34. Barr JT, Schumacher GE, Freeman S, et al. American translation, modification, and validation of the St. George's Respiratory Questionnaire. Clin Thei 2000;22:1121-45.